Orion Achieves Positive Operating Income and Continued Growth in Revenue and Profitability in Q3 2026; Reiterates Increase in FY 2026 Expectation and Establishment of FY 2027 Outlook
Globenewswire· 2026-02-05 12:00
MANITOWOC, Wisc., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today reported results for its fiscal 2026 third quarter (Q3’26) ended December 31, 2025. Orion’s Q3’26 revenue was $21.1M vs. $19.6M in Q3’25, while Q3’26 Gross Profit Percentage was 30.9% vs. 29.4% in Q3’25. The Company achieved positive operating income in Q3’26 and adjusted ...
Kling AI Launches 3.0 Model, Ushering in an Era Where Everyone Can Be a Director
Globenewswire· 2026-02-05 12:00
HONG KONG, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Kuaishou Technology ("Kuaishou" or the "Company"; HKD Counter Stock Code: 01024 / RMB Counter Stock Code: 81024), a leading content community and social platform, today announced the launch of its Kling AI 3.0 models — including Video 3.0, Video 3.0 Omni, Image 3.0 and Image 3.0 Omni — giving creators greater narrative control and stronger consistency in AI video generation. The model series features major upgrades in consistency, photorealistic output, extended ...
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Globenewswire· 2026-02-05 12:00
SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on SOL-1 52 Week data, pending positive results and planned FDA interactions Completed randomization of 631 subjects in SOL-R Phase 3 non-inferiority trial in December 2025; timing of topline results accelerated and now anticipated in 1Q 2027 HELIOS-3 Phase 3 trial in diabetic retinopathy underway Cash balance of ...
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
Globenewswire· 2026-02-05 12:00
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, at 12:30 p.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay ...
Westhaven Appoints Anderson to Board of Directors and Grants Stock Options
Globenewswire· 2026-02-05 12:00
VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Westhaven Gold Corp. (TSX-V: WHN) (“Westhaven” or the “Company”) is pleased to announce the appointment of Mr. Patrick F.N. Anderson to its Board of Directors as an Independent Director. Eira Thomas, Chairperson of Westhaven, commented, “We are very pleased to welcome Patrick Anderson to Westhaven’s Board. Patrick has an exceptional track record of discovery and development of world-class gold deposits, including the best-in-class Fruta del Nort ...
Baker Hughes to Provide Downstream Chemicals for Marathon Petroleum Refineries, Becoming Preferred Provider Across North America
Globenewswire· 2026-02-05 12:00
Solutions will be implemented at 12 refineries and 2 renewable fuels facilitiesChemical technologies and digital monitoring tools designed to optimize operational efficiency HOUSTON and LONDON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ: BKR), an energy technology company, announced Thursday an agreement with Marathon Petroleum, the largest U.S. petroleum refiner, to become its preferred provider for hydrocarbon treatment products and services at refineries across the United States. The multiyea ...
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Globenewswire· 2026-02-05 12:00
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplantREDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100/TG-0054), a highly selective ...
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Globenewswire· 2026-02-05 12:00
FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA li ...
RTC of Southern Nevada exercises option for 50 more low-emission buses from NFI subsidiary New Flyer
Globenewswire· 2026-02-05 12:00
ST. CLOUD, Minn., Feb. 05, 2026 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) New Flyer of America Inc. (New Flyer), a leading provider of diverse and sustainable mobility solutions and subsidiary of NFI Group Inc. (NFI), has confirmed that the Regional Transportation Commission of Southern Nevada (RTC) is exercising options for 19 sixty-foot and 31 forty-foot Xcelsior® compressed natural gas (CNG) buses. This order was included in NFI’s fourth quarter 2025 firm backlog. Valued at approximately $ ...
Peloton Announces Q2 FY2026 Financial Results
Globenewswire· 2026-02-05 12:00
Delivered Year-over-Year Improvement in Profitability While Investing in Ambitious Innovation Agenda Raises Full Year FY2026 Adjusted EBITDA Guidance to $450 - $500 million* NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Peloton Interactive, Inc. today reported financial results for the quarter ended December 31, 2025. Q2 FY2026 Financial Highlights Ending Paid Connected Fitness Subscriptions were 2.661 million, a decrease of 214,000 or 7% year-over-year and 6,000 above the midpoint of our guidance range. We o ...